Figure 2. Comparisons of primary outcomes between gemcitabine-containing and non–gemcitabine-containing regimens.
(A) Overall survival, (B) Progression free survival, (C) Objective tumor response rate.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.